Harmonet (Ethinylestradiol, Gestodene)

Harmonet is indicated for the prevention of pregnancy in women of reproductive age.

• Primary indication: combined hormonal contraception to prevent pregnancy.
• Used in a regular 21‑day active tablet regimen followed by a hormone‑free interval.
• May help regulate menstrual cycle timing and flow.
• Can be prescribed after childbirth, abortion, or miscarriage when no contraindications exist.
• Suitable for women who are non‑smokers or light smokers under 35 years of age.
• May be considered for women seeking a reversible, user‑controlled contraceptive method.

Side effects of Harmonet vary in frequency and severity.

Common

• Nausea or mild gastrointestinal discomfort.
• Breast tenderness or enlargement.
• Headache, including tension‑type headaches.
• Irregular vaginal bleeding or spotting between periods.
• Mood changes such as irritability or mild depression.
• Weight fluctuations or fluid retention.

Serious

• Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism).
• Arterial thrombosis leading to stroke or myocardial infarction.
• Severe hypertension or hypertensive crisis.
• Liver dysfunction, including cholestatic jaundice.
• Allergic reactions such as rash, angioedema, or anaphylaxis.
• Visual disturbances or ocular migraines.

Before prescribing Harmonet, clinicians should evaluate several safety considerations.

• Not recommended for women over 35 who smoke heavily (≥15 cigarettes per day).
• Contraindicated in individuals with a history of thromboembolic disorders or clotting disorders.
• Caution in patients with uncontrolled hypertension, diabetes with vascular disease, or migraine with aura.
• Avoid use in women with known or suspected estrogen‑dependent tumors (e.g., breast cancer).
• Liver disease, especially severe hepatic impairment, requires careful assessment.
• Women who are pregnant or suspect pregnancy should not start Harmonet.
• Regular monitoring is advised for women with gallbladder disease or lipid abnormalities.

Drug interactions can affect the efficacy of Harmonet or increase adverse event risk.

Avoid

• Strong enzyme inducers such as rifampin, phenytoin, carbamazepine, and St. John's wort, which may reduce contraceptive effectiveness.
• Concomitant use with selective serotonin reuptake inhibitors (SSRIs) that significantly increase bleeding risk.

Use with caution

• Antiepileptic drugs (e.g., valproate, lamotrigine) that may require dose adjustments.
• Azole antifungals (ketoconazole, fluconazole) that can increase hormone levels.
• HIV protease inhibitors (ritonavir) that may alter hormone metabolism.
• Certain antibiotics (e.g., griseofulvin) that have modest enzyme‑inducing properties.
• Herbal supplements that affect liver enzymes, such as ginseng or black cohosh.